EDOLAS
Efficacy and safety of early switching to dolutegravir/lamivudine (DTG/3TC) from INSTI-based three-drug regimens in HIV-1-infected adults previously naïve who achieve virological suppression
FORGOT PASSWORD?
Clinical Research Technology
Web solutions provided by
www.cr-technology.com
(
info@cr-technology.com
)
Helpdesk:
edolas@cr-technology.com